Irish company Covidien has secured 510(k) approval from US Food and Drug Administration (FDA) for its HawkOne directional atherectomy system.
The new system features an improved cutting mechanism, allowing physicians to treat a wide range of plaque in patients with peripheral arterial disease (PAD).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The disease affects more than 202 million people worldwide and more than ten million people in the US.
PAD occurs when arteries in the legs become narrowed or blocked by plaque, and it can result in severe pain, limited physical mobility and non-healing leg ulcers.
The disease can also lead to serious health consequences such as amputation, cardiovascular disease and death.
Covidien peripheral vascular president Brian Verrier said: "Covidien is committed to being the clear first choice for our physician and hospital partners by delivering new innovative technologies that help save and improve patient lives.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData"The FDA clearance of the HawkOne system enhances our leading peripheral vascular portfolio and further demonstrates Covidien’s leadership in the atherectomy space."
The company’s directional atherectomy portfolio comprises of TurboHawk and SilverHawk systems, which were evaluated by more than 15 peer-reviewed trials.
Recent published data from the DEFINITIVE LE trial showed 95% limb salvage in patients with critical limb ischemia (CLI) and 78% overall patency in claudicant patients at 12 months following treatment with directional atherectomy.
Covidien has more than 38,000 employees and operates in 150 countries with a reported revenue of $10.2bn in 2013.
